Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — FY2024 Earnings Presentation
19 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Feb 25, 2025
Slide 1: Earnings Presentation FY 2024
Earnings Presentation FY 2024 Jeddah | 25 February 2025
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 3: Business and Strategy Highlights
Business and Strategy Highlights
Slide 4: FY 2024 highlights: Revenue over SAR 1.3Bn, NP margin at 27%
4 Business and Strategy Highlights FY 2024 highlights: Revenue over SAR 1.3Bn, NP margin at 27% Revenue Record revenue continues growing at a 3- # of Brands 9 new launches including 4 in Consumer year CAGR of 20%, fueled by strategic market FY 24 +20% YoY Health, 2 in Anti-Diabetic, 1 each in penetr
Slide 5: 2024 recap
5 Business and Strategy Highlights 2024 recap • Overall retail market grew 18% (11% ex-weight loss diabetes drugs)1 Saudi Market • JP achieves 7th rank (in overall KSA market2) up from 12th in 2020 • JP achieves 3rd rank (in KSA Retail market3) • JP’s own tender sales grew 26% (overall KSA sales gre
Slide 6: Jamjoom Pharma's strategy at a glance
6 Business and Strategy Highlights Jamjoom Pharma’s strategy at a glance Vision To become the leading MEA organization by 2030 through consistently providing affordable, high- quality healthcare solutions Portfolio Focus Niche TA’s Specialty / Biologics Consumer leadership cardio & Hi-tech health me
Slide 7: Production grows at Jeddah Main Facility whilst Cairo ramps up
7 Business and Strategy Highlights Production grows at Jeddah Main Facility whilst Cairo ramps up SAR 100bn+ of Total Addressable Market Jeddah Jeddah Cairo Algiers* in Core Geographies By 2027 Main Facility Sterile Facility Main Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom of Saudi Ara
Slide 8: Accelerating revenue growth in strategic therapeutic areas and regions
8 Business and Strategy Highlights Accelerating revenue growth in strategic therapeutic areas and regions Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +20% +20% 11 13 12 1,318 35 19 27 16 11 1,318 30 42 11 73 137 1,101 1,101 +46% units sold 66% l
Slide 9: 4th Quarter 2024 highlights
9 Business and Strategy Highlights 4th Quarter 2024 highlights Revenue (SARmn) EBITDA (SARmn) +24% +33% 260 209 72 54 EBITDA Margin 25.9% 27.7% 4Q 23 4Q 24 4Q 23 4Q 24 FCF (SARmn) Net Profit (SARmn) +36% +16% 62 In Q4 2024, a one-off provision of SAR 52 44 5.1 million was charged against 45 legacy i
Slide 10: Pipeline overview: cardiometabolic a strategic focus for future growth
10 Business and Strategy Highlights Pipeline overview: cardiometabolic a strategic focus for future growth Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 6 15 7 2 General Medicine 1 3 Dermatology Revenue growth EBITDA 1 3 margin 2 4 Consumer Health 6 12 2 1 Gastr
Slide 11: Portfolio diversification update
11 Business and Strategy Highlights Portfolio diversification update 2021 Revenue Contribution by Therapeutic Area (SARmn) 2024 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation 5% Anti-diabetic 27% C. Nervous System Ophthalmology 2% Ophthalmology 2% Cardiovascular 6% 32% Pain & I
Slide 12: Transforming JP leadership: 4 new executives join the team in 2025
12 Business and Strategy Highlights Transforming JP leadership: 4 new executives join the team in 2025 Previous experience Previous experience Tarek Hosni Alaa Al-Zaghah Chief Executive Officer Chief Transformation & Marketing Officer 38 4 25 New Anwer Mohiuddin Haitham Aqel Chief Financial Officer
Slide 13: Financial Highlights
A LojLa pagan Jamjoom Pharma Financial Highlights
Slide 14: Driving operational efficiency to combat rising costs…
14 Financial Highlights Driving operational efficiency to combat rising costs… Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +25% +9% 11 7 498 26 30 5 422 386 1 57 G&A/Sales 397 R&D/Sales down S&D/Sales down 61bps 45bps YoY down 2pps YoY YoY +2% +11% +8% FY 23 R&
Slide 15: … and deliver sustainable profit growth
15 Financial Highlights … and deliver sustainable profit growth EBITDA Movement YoY (SARmn) EBITDA and Net Profit Margins, Quarterly (%) +27% 35.4% 218 33.8% 34.1% EBITDA Margin 33.2% 25.9% 27.7% 11 437 EBITDA Margin 31.1% (101) 30.9% 29.0% (30) (5) 344 26.7% 21.3% 19.9% Successful operating efficie
Slide 16: Efficient cash conversion aligned with robust business growth
16 Financial Highlights Efficient cash conversion aligned with robust business growth Cash Conversion Cycle (Days) ▪ Cash conversion cycle expanded by a CAGR of only 1% since FY 2022 amidst revenue CAGR was 19.9% for the same period. This reflects successful management of our working capital amidst
Slide 17: Outlook and Guidance
A LojLa pagan Jamjoom Pharma Outlook and Guidance
Slide 18: Financial guidance: 2024 targets met with a strong future outlook
18 Outlook and Guidance Financial guidance: 2024 targets met with a strong future outlook FY 24 Guidance FY 24 Actual Results FY 25-27 Guidance Revenue growth 15-18% 19.8% 12-15% EBITDA margin 31-32.5% 33.2% 30.0-31.5% CAPEX 4-6% 4.3% 4-6% FY24 dividend of SAR 3.1/share Dividend 50-60% payout ratio
Slide 19: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — FY2024 Earnings Presentation on 6ix